S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
Log in

NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

$0.48
-0.02 (-4.61 %)
(As of 04/1/2020 02:01 PM ET)
Today's Range
$0.44
Now: $0.48
$0.48
50-Day Range
$0.39
MA: $0.58
$0.79
52-Week Range
$0.37
Now: $0.48
$2.40
Volume5,391 shs
Average Volume196,472 shs
Market Capitalization$19.84 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.76
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.
Read More
Innovate Biopharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INNT
CUSIPN/A
Phone919-275-1933

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.27) per share

Profitability

Net Income$-27,050,000.00

Miscellaneous

Employees8
Market Cap$19.84 million
Next Earnings Date5/8/2020 (Estimated)
OptionableOptionable

Receive INNT News and Ratings via Email

Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.


Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions

How has Innovate Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INNT shares have increased by 1.8% and is now trading at $0.48. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Innovate Biopharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innovate Biopharmaceuticals.

When is Innovate Biopharmaceuticals' next earnings date?

Innovate Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Innovate Biopharmaceuticals.

How were Innovate Biopharmaceuticals' earnings last quarter?

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). View Innovate Biopharmaceuticals' earnings history.

Has Innovate Biopharmaceuticals been receiving favorable news coverage?

Media stories about INNT stock have trended very positive recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the next several days. View the latest news aboutInnovate Biopharmaceuticals.

Are investors shorting Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,243,800 shares, an increase of 7.9% from the February 27th total of 2,080,000 shares. Based on an average trading volume of 215,300 shares, the days-to-cover ratio is presently 10.4 days. Approximately 7.9% of the shares of the company are short sold. View Innovate Biopharmaceuticals' Current Options Chain.

Who are some of Innovate Biopharmaceuticals' key competitors?

What other stocks do shareholders of Innovate Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Axsome Therapeutics (AXSM), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Who are Innovate Biopharmaceuticals' key executives?

Innovate Biopharmaceuticals' management team includes the following people:
  • Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)
  • Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)
  • Dr. Christopher P. Prior, Consultant (Age 66)
  • Jerry Gardner M.D., Head of Clinical Strategy
  • Dr. Patrick H. Griffin, Chief Medical Officer (Age 64)

What is Innovate Biopharmaceuticals' stock symbol?

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

How do I buy shares of Innovate Biopharmaceuticals?

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Innovate Biopharmaceuticals' stock price today?

One share of INNT stock can currently be purchased for approximately $0.48.

How big of a company is Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals has a market capitalization of $19.84 million. The company earns $-27,050,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe. View additional information about Innovate Biopharmaceuticals.

What is Innovate Biopharmaceuticals' official website?

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

How can I contact Innovate Biopharmaceuticals?

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]


MarketBeat Community Rating for Innovate Biopharmaceuticals (NASDAQ INNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  202 (Thanks for Voting!)
Underperform Votes:  214 (Thanks for Voting!)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote "Outperform" if you believe INNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel